Interleukin 12: still a promising candidate for tumor immunotherapyReport as inadecuate




Interleukin 12: still a promising candidate for tumor immunotherapy - Download this document for free, or read online. Document in PDF available to download.

Cancer Immunology, Immunotherapy

, Volume 63, Issue 5, pp 419–435

First Online: 11 February 2014Received: 15 November 2013Accepted: 20 January 2014DOI: 10.1007-s00262-014-1523-1

Cite this article as: Lasek, W., Zagożdżon, R. & Jakobisiak, M. Cancer Immunol Immunother 2014 63: 419. doi:10.1007-s00262-014-1523-1

Abstract

Interleukin 12 IL-12 seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate NK cells and adaptive cytotoxic T lymphocytes immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened  hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines IL-12 fused to monoclonal antibodies. The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.

KeywordsInterleukin 12 Cancer immunotherapy Gene therapy Cytokine  Download fulltext PDF



Author: Witold Lasek - Radosław Zagożdżon - Marek Jakobisiak

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents